Patent · US Active

Targeting BCL11A distal regulatory elements with a CAS9-CAS9 fusion for fetal hemoglobin reinduction

US12098363B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignees

Children's Medical Center Corporation · US
University of Massachusetts · US

Inventors

Daniel E. Bauer · Cambridge, US
Scot Andrew Wolfe · Winchester, US
Mehmet Fatih Bolukbasi · Worcester, US
Benjamin Roscoe · Worcester, US
Pengpeng Liu · Worcester, US
Kevin Luk · Worcester, US
Yuxuan Wu · Taizhou City, CN
Jing Zeng · Shanghai, CN

Key dates

Filing date	Jul 20, 2018
Grant date	Sep 24, 2024
Priority date	—
Expiry date	May 14, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/80
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.